AstraZeneca promotes oncology exec to CMO; Pfizer replaces retiring chief dealmaker as war chest expands
The biggest bright spot for AstraZeneca over the last few years has been its work in oncology, as CEO Pascal Soriot has helped shepherd blockbusters Imfinzi, Lynparza, and Calquence, among other cancer medicines.
One of the top executives from the cancer division is now making the leap to the larger C-suite. The Swedish-British pharma named its oncology chief development officer Cristian Massacesi as the new CMO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.